Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Fulvestrant × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 292 Neoplasm Metastasis 28 Advanced Breast Cancer 17 Neoplasms 14 Ovarian Neoplasms 11 Hereditary Sensory and Autonomic Neuropathies 8 Prostatic Neoplasms 6 Endometrial Neoplasms 6 Triple Negative Breast Neoplasms 5 Breast Diseases 5 Breast Cancer Metastatic 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neoplasms by Site 4 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Multiple Endocrine Neoplasia Type 1 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Recurrence 2 Pancreatic Neoplasms 2 Liposarcoma 2 Hyperglycemia 2 HER2-positive Metastatic Breast Cancer 2 HER2-positive Breast Cancer 2 Fallopian Tube Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Estrogen Receptor Positive Breast Cancer 2 Carcinoma, Ductal, Breast 2

Interventions

capivasertib 2 tremelimumab 1 grapiprant 1 durvalumab 1 Standard of Care 1 Practice Guidelines as Topic 1 Palliative Care 1 Gemcitabine 1 Fulvestrant 1 Clinical Trials, Phase II as Topic 1 Clinical Trials, Phase I as Topic 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-01-13

CAPItrue

AstraZeneca

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡